News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
U.S. Panel Backs Dendreon Corporation’s Provenge for Medicare
November 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp's Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Policy
FDA Policy Tracker 2026: RMAT Awards for Assets on Hold, Animal Testing Alternatives
March 19, 2026
·
9 min read
·
BioSpace Editorial Staff
Legal
Kennedy’s Vaccine Policy Overhaul Stymied by Federal Judge
March 17, 2026
·
3 min read
·
Tristan Manalac
Government
As Midterms Loom, White House Cracks Down on RFK Jr.’s Vaccine Policies—but MAHA Resists
March 16, 2026
·
4 min read
·
Tristan Manalac
Editorial
Prasad’s Request To Remain Anonymous Shines Light on FDA’s Transparency Problem
March 13, 2026
·
7 min read
·
Heather McKenzie
